FDA approves first generic GLP-1 for weight loss, a copy of Saxenda (liraglutide)

Teva received FDA approval for, and launched, a generic version of Saxenda (liraglutide injection), the first generic GLP-1 receptor agonist indicated for chronic weight management, for adults and for adolescents aged 12 to 17 weighing more than 60 kg. It followed the FDA's December 2024 approval of the first generic of Victoza, the type 2 diabetes version of liraglutide, from Hikma. Teva put branded Saxenda's annual US sales at about $165 million.